Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

This study is developed by the investigator and is a, phase I, single arm, clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome. The types of treatments given will be shared with participants. The aims are: 1. To assess the safety and how well the participants tolerate the treatment 2. Assess the response of the tumor to treatment to estimate complete response 3. Assess the response of the tumor to treatment to estimate progression-free survival

Trial Details

NCT ID

NCT06977711

Phase

PHASE1

Sponsor

The University of Texas Health Science Center at San Antonio

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Loncastuximab
Roflumilast
Rituximab
Cyclophosphamide
Vincristine
Doxorubicin

Locations (sample)

San Antonio, Texas, United States|29.42412,-98.49363
San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

Men and women 18 years of age or older.
Pathologically proven diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS).
\- Patients with Diffuse large B-cell lymphoma/ high grade B-cell lymphoma with MYC (myelocytomatosis oncogene) and BCL2 (B-cell lymphoma 2) rearra…
No prior systemic therapy for lymphoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →